PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Malaysia Diagnostics and Devices Industry Outlook 2009 - Frost & Sullivan - The current economic downturn has contributed to a significant shift in the Healthcare industry, but not for Malaysia
Malaysia Diagnostics and Devices Industry Outlook 2009

 

NewswireToday - /newswire/ - Kuala Lumpur, Malaysia, 2009/08/21 - Frost & Sullivan - The current economic downturn has contributed to a significant shift in the Healthcare industry, but not for Malaysia.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Nitin Naik, Vice President of the Healthcare, Asia Pacific says that the total Healthcare Expenditure grew at 13.70% CAGR from 2003 to 2008, which stood at US$ 7.6 billion in 2008 (up from US$ 4 billion in 2003). Healthcare expenditure in Malaysia is increasing driven by increased privatization within the healthcare service provision and upgrading of existing healthcare infrastructure within the public sector. The market for healthcare services has also received positive impetus from the growing promotion of health tourism and development activities.

"In particular the Diagnostics market in Malaysia stands at CAGR of 10.5% with expenditure allocations of USD45mil if judged against the other neighborhood country such as Singapore, with CAGR of 5.5% and expenditure allocations of USD24mil," he further comments.

Three of the segments that make up over 60% of the total diagnostics market are Immuno-Chemistry, Clinical Chemistry and Self Monitoring Blood Glucose (SMBG). The growing demand of SMBG devices is due to the increasing ageing population in many Asian countries and prevalence of diabetes. Most of the segments are expected to grow fairly due to emerging focus on preventative medicines in Asia.

Naik elaborates that, to further compliment the diagnostics market "diagnostics companies are expanding and combining expertise to allow respective companies to make significant contributions to diagnostics and patient care. Oncology companies are coming together to move to the forefront of diagnostics technology and to provide full range of solutions between diagnostics and therapy. With this, Molecular Diagnostics companies are able to join their cutting edge, life saving technologies and superior customer service through alliances while complementing automated diagnostics solutions for hospitals to provide clinicians with quicker and more accurate results."

Advancement in technology has also enhanced the future trend of the diagnostics market via the implementation of Nanotechnology, Molecular and Gene-based Diagnostic, Information Technology, Artificial Organs and Tissue Engineering. The technological advancement will bring several benefits in various aspects to patients by improving affordability, user friendly, long term monitoring, self testing and cater to specialized needs of individual patients' health situation.

Surviving in this dynamic diagnostics market, there are some restraining factors that would affect the market from growing as planned. Some of the restraining factors that should be taken into consideration would be low level of Research & Development from local manufacturers, lack of awareness by health professionals, lack of universal connectivity, industry consolidation suppress and passive public involvement.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

Contact:
Jasminder Kaur
Corporate Communications –Healthcare, Asia Pacific
DID: +65 6890 0937
E: jkaur[.]frost.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Malaysia Diagnostics and Devices Industry Outlook 2009

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Emmie Kaur 
+603 6204 5913 emmie.kaur[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  BizJobs.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)